Briacell Therapeutics Corp宣布,已与富士胶片生物技术加州公司就其实验性癌症免疫疗法Bria-IMT达成了生产安排。该协议旨在为Bria-IMT的临床开发和未来潜在的商业化提供支持。
Briacell Therapeutics Corp宣布,已与富士胶片生物技术加州公司就其实验性癌症免疫疗法Bria-IMT达成了生产安排。该协议旨在为Bria-IMT的临床开发和未来潜在的商业化提供支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.